Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window

Stock News

Merus Shares Surge with Impressive Interim Cancer Trial Data

Jack KelloggAvatar
Written by Jack Kellogg
Updated 5/29/2025, 11:32 am ET 4 min read

Merus N.V. stocks have been trading up by 8.68 percent following FDA designations and promising clinical trial results.

Key Takeaways

  • Petosemtamab’s interim phase 2 trial data reveal 79% overall survival in 12 months, turning heads in the medical community and investor circles.
  • Shares skyrocketed by 36% due to substantial trading volumes driven by the successful trial results.
  • The study emphasizes the impressive efficacy of petosemtamab with pembrolizumab, heralding a new era in targeted cancer therapy.
  • The latest findings may reshape treatment standards for head and neck cancer, with results favorably contrasting with existing therapies.
  • Promising developments have cemented Merus’ position as a leader in cancer treatment innovations, sending positive ripples across the sector.

Candlestick Chart

Live Update At 11:32:12 EST: On Thursday, May 29, 2025 Merus N.V. stock [NASDAQ: MRUS] is trending up by 8.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

More Breaking News

The recent financial report depicts a dramatic revenue growth to $26.5M in Q1 2025. Although lofty expenses persist, as seen in a trailing cash flow downside of $96M, it’s the colossal $457M in cash and short-term investments that fortify Merus’ financial stronghold. Their strategic cash allocation further extends its viable runway well into 2028. Despite a steep price-to-sales ratio of 64.2x, the aggressive revenue surge and effective strategy standings have assured a long trajectory ahead. Analysts remain cautiously positive as a profit margin of negative 507% underlines gap closures still required. A bustling sales surge of 1.45% year-on-year resonates Marus’ resilience and foresight.

Market Reactions and Impacts

May 23 was an unequivocal triumph for Merus, marked by a massive price ascent. The catalyst: resounding success from a pivotal phase 2 cancer trial epitomizes Merus’ edge. Head and neck squamous cell carcinoma patients saw remarkable outcomes. Petosemtamab in tandem with pembrolizumab proved best-in-class, registering a towering 79% survival projection within a 12-month span. Sentiments rallied investor excitement, as healthcare sectors eyed Merus’ groundbreaking results. The price trajectory soared, framed by strategic foresight and a clinical approach, driving stock prices upwards by leaps and bounds. The implications stretch far beyond financial foreshadowing, possibly redefining how resistant cancer types will be combated henceforth.

Conclusion

The momentum seen in the Merus narrative underscores a blend of scientific achievement and astute financial management. With communal anticipation ensuing from their latest findings, Merus appears poised to solidify its pioneering role within biotechnology sectors. The asset turnover foreshadows a promising financial recovery bound by strategic initiatives being rolled out. As these strategic initiatives take shape, traders are keenly aware of market dynamics, and as millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” Previously noted operational hiccups are gradually morphing into past strains, paving a clear path towards sustainable growth. As medical communities embrace Merus’ triumphs, its potential to disrupt existing treatment modalities remains exponentially viable. The excitement brewing isn’t just speculative—it heralds an advancing paradigm shift right within oncology landscapes.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More


* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications